

Submitted: 13.03.2022 Accepted: 28.04.2022 Early publication date: 28.07.2022 Endokrynologia Polska DOI: 10.5603/EP.a2022.0054 ISSN 0423–104X, e-ISSN 2299–8306 Volume/Tom 73; Number/Numer 5/2022

Genome-wide association study of fasting proinsulin, fasting insulin, 2-hour postprandial proinsulin, and 2-hour postprandial insulin in Chinese Han people

Leweihua Lin¹, Huibiao Quan¹, Tuanyu Fang¹, Lu Lin¹, Qianying Ou¹, Huachuan Zhang², Kaining Chen¹, Zhiguang Zhou³

¹Department of Endocrinology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, China ²Laboratory of Endocrine, Hainan General Hospital, Haikou, Hainan Province, China ³Department of Endosecretory Metabolic Diseases, The Second Xiangya Hospital of Central South University, Changsha,

Hunan Province, China

Abstract

Introduction: Fasting proinsulin (FPI) and fasting insulin (FI) have been demonstrated to be associated with impaired β-cell function, T2DM, and insulin resistance. This genome-wide association study (GWAS) was performed to contribute to our understanding of the genetic basis of FPI, FI, 2-hour postprandial proinsulin (2hPI), and 2-hour postprandial insulin (2hI) of the pathophysiology of prediabetes in the Chinese population. **Material and methods:** The levels of fasting plasma glucose (FPG), FPI, FI, 2hPI, and 2hI were examined by an automatic biochemical analyser. The Applied BiosystemsTM AxiomTM Precision Medicine Diversity Array, the Gene Titan Multi-Channel instrument, and Axiom Analysis Suite 6.0 Software were used for genotyping. Imputation was performed with IMPUTE 2.0 software from HapMap, 1000 Genomes Phase 3 as a reference panel.

Results: Six single nucleotide polymorphisms (SNPs) in *DLG1-AS1*, *SORCS1*, and *CTAGE11P* for FPI, and 27 SNPs in *ZNF718*, *MARCHF2*, and *HNRNPM* for 2hPI reached genome-wide significance. Genome-wide significance was reached for associations of 6 SNPs in *KRT71* to FI. Also, 14 SNPs in *UBE2U*, *ABO*, and *GRID1-AS1* were genome-wide significant in their relationship with 2hI. Among these, the genetic loci of *CTAGE11P*, *MARCHF2*, *KRT71*, and *ABO* have the strongest association with FPI, 2hPI, FI, and 2hI.

Conclusions: The genetic variants of *CTAGE11P*, *MARCHF2*, *KRT71*, and *ABO* are significantly correlated with FPI, 2hPI, FI, and 2hI, respectively, in Chinese Han people. These genetic variants may serve as new biomarkers for the prevention of prediabetes. **(Endokrynol Pol 2022; 73 (5): 856–862)**

Key words: GWAS; fasting proinsulin (FPI); fasting insulin (FI); 2hPI; 2hI

Introduction

Diabetes mellitus (DM) is a chronic metabolic disease caused by abnormal glucose metabolism, which is mainly characterized by hyperglycaemia. There are approximately 382 million people affected with DM worldwide, and type 2 diabetes mellitus (T2DM) accounts for 90% of DM patients [1, 2]. Prediabetes refers to blood glucose levels above normal but below diabetes thresholds. The prevalence of prediabetes is increasing worldwide, and it is estimated that 470 million people will suffer from prediabetes in 2030 [3]. In China, it is reported that the overall prevalence of diabetes is 10.9% and that for prediabetes it is 35.7% [4]. It has been demonstrated that prediabetes is a high-risk state of diabetes, and it also increases the risk of myocardial infarction, stroke, and cardiovascular death [5]. There is accumulating evidence to demonstrate that prediabetes could cause damage to the kidneys and the nervous system [6, 7]. Additionally,

prediabetes imposes a huge economic burden on individuals and society [8]. Therefore, effective prevention strategies for prediabetes are increasingly important.

Proinsulin (PI), the precursor form of insulin (I), is synthesized and secreted in pancreatic β -cells. PI only accounts for 10-20% of fasting insulin (FI) under physiological conditions. However, some research indicates that the level of PI was highly expressed in glucose-intolerant and insulin-resistant individuals [9, 10]. Also, fasting proinsulin (FPI) has been demonstrated to be associated with impaired β -cell function, T2DM and insulin resistance, and it could be used as a specific predictor of T2DM [10, 11]. Insulin is a well-known hormone to reduce the level of blood glucose via the stimulation of glucose uptake into muscle cells and adipocytes, etc. by binding to its receptor in the target cells. It has been shown that elevated fasting insulin (FI) is a hallmark of T2DM [12]. Our previous study demonstrated that FPI, 2-hour postprandial proinsulin (2hPI), FI, and 2-hour postprandial insulin (2hI)

Huibiao Quan, #19 Xiuhua Road, Xiuying District, Haikou, Hainan Province, 570311, China, tel: +86 13876078153; e-mail: qhb13876078153@hainmc.edu.cn were associated with an increased risk of prediabetes [13]. Despite these findings, it is still unclear how these common phenotypes affect T2DM.

In this study, we performed a genome-wide association study (GWAS) of FPI, 2hPI, FI, and 2hI in 451 prediabetes subjects from the Chinese Han population. The Biosystems[™] Axiom[™] Precision Medicine Diversity Array (PMDA) was used to identify single nucleotide polymorphisms (SNPs) associated with FPI, 2hPI, FI, and 2hI. Our study will provide an effective diagnostic method for early screening of people who are susceptible to T2DM, and for controlling and preventing the development of prediabetes to T2DM.

Material and methods

Participants

In this study, we recruited 451 prediabetes subjects aged \geq 18 years from the Hainan Affiliated Hospital of Hainan Medical University. Participants with 100 mg/dL (5.6 mmol/L) \leq fasting plasma glucose < 125 mg/dL (6.9 mmol/L) or 5.7% \leq glycated haemoglobin (HbA₁,) < 6.4% were defined as prediabetes [14]. Individuals without a history of diabetes and malignant tumours, or severe liver and kidney diseases were included in this research. This study was conducted with ethical approval from the Hainan Affiliated Hospital of Hainan Medical University Ethics Committees, and was performed in line with the Declaration of Helsinki. We also obtained consent forms signed by each participant.

Metabolic variables

Fasting blood samples were collected from all subjects after an overnight fast. The levels of fasting plasma glucose (FPG), FPI, FI, 2hPI, and 2hI were examined by an automatic biochemical analyser.

Genotyping and imputation

Genomic DNA was isolated from a whole blood sample using a DNA Extraction Kit (GoldMag Co. Ltd., Xi'an, China), as described previously [15]. The Applied BiosystemsTM Axiom TM Precision Medicine Diversity Array (PMDA, Thermo Scientific, USA), the Gene Titan Multi-Channel instrument, and Axiom Analysis Suite 6.0 Software were used for genotyping.

Genotype data in subjects was cleaned using standard thresholds (HWE p > $5 \times 10^{\circ}$, call rate > 95%). Imputation for chromosomes 1 to 22 was performed with IMPUTE 2.0 software from HapMap 1000 Genomes Phase 3 as a reference panel.

Statistical analyses

The association analysis was conducted using Gold Helix SNP and Variation Suite 8.7 software. The association between SNPs and FPI, 2hPI, FI, and 2hI was evaluated using linear regression assuming an additive genetic model. The 4 traits were analysed with adjustments for age and sex. A p < 5.0×10^{-6} was used as the threshold of genome-wide significance.

Results

A total of 451 prediabetes individuals aged \geq 18 years (216 men and 235 women) were included and genotyped in the present study. The average age of the subjects was 51.78 ± 14.49 years. The clinical parameters of participants are summarized in Table 1. Table 1. Participants characteristics

| Variable | Subjects |
|----------------------------|-------------------|
| Number of individuals | 451 |
| Age (years, mean \pm SD) | 51.78 ± 14.49 |
| Gender | |
| Male | 216 (47.9%) |
| Female | 235 (52.1%) |
| FPG [mmol/L] | 5.88 ± 1.42 |
| FPI [mU/L] | 15.74 ± 12.18 |
| 2hPI [mU/L] | 63.42 ± 44.10 |
| FI [mU/L] | 72.10 ± 43.08 |
| 2hl [mU/L] | 578.22 ± 435.40 |
| | |

FPG — fasting plasma glucose; FPI — fasting proinsulin; 2hPI — 2-hour postprandial proinsulin; FI — fasting insulin; 2hI — 2-hour postprandial insulin; SD — standard deviation

As presented in Table 2, we found that 6 loci in 3 genes (*DLG1-AS1, SORCS1, CTAGE11P*) reached genome-wide significance associated with FPI, and 27 SNPs in 3 genes (*ZNF718, MARCHF2,* and *HNRNPM*) were associated with 2hPI. In addition, the correlation of 6 SNPs in the *KRT71* gene with FI reached genome-wide significance. Also, 14 SNPs in 3 genes (*UBE2U, ABO,* and *GRID1-AS1*) were genome-wide significant in their relationship with 2hI. The distributions of association p-values for FPI, 2hPI, FI, and 2hI are presented in Figure 1 (the quantile-quantile plots and Locus zoom are shown in Fig. S1 and Fig. S2). Among these, the genetic loci of *CTAGE11P, MARCHF2, KRT71,* and *ABO* have the strongest association with FPI, 2hPI, FI, and 2hI, respectively.

Discussion

The current study illustrated that the genetic variants of *CTAGE11P*, *MARCHF2*, *KRT71*, and *ABO* were significantly correlated with FPI, 2hPI, FI, and 2hI in Chinese Han people, respectively. Our research will provide scientific methods and ideas for the prevention and diagnosis of prediabetes, and it will contribute to controlling and reducing the progression of prediabetes to T2DM.

Recently, GWAS was performed by Strawbridge et al., which found that 9 SNPs in 8 genes were associated with FPI levels in the European population [16]. Subsequently, Huyghe et al. also identified low-frequency coding variants associated with FPI at SGM2 and MADD gene in Finnish males [17]. Moreover, it is suggested that IGF-1 genetic variants were associated with FI in European ancestry [18]. Manning et al. also observed that 6 SNPs in *COBLL1-GRB14, IRS1, PPP1R3B, PDGFC, UHRF1BP1,* and *LYPLAL1* are correlated with the FI level [19]. However, those SNPs explained only

| 5 |
|---------------|
| 7 |
| Ż |
| Ż |
| Ż |
| Ż |
| Ż |
| Ż |
| Ż |
| Ż |
| Z |
| Z |
| ZIS |
| SIN |
| ZIN |
| GIN |
| GIN |
| GIN |
| IGIN |
| IGIN |
| IGIN |
| IGIN |
| NIGIN, |
| NIGIN |
| SIGIN |
| RIGIN |
| RIGIN |
| RIGIN |
| RIGIN |
| IRIGIN |
| RIGIN |
| DRIGIN |
| ORIGIN |

| DCI: Arisino Control FI DCI antenses INAI C 2012 C 202 C 202 <thc 202<="" th=""> C 202 C 202 <t< th=""><th>Gene</th><th>Traits</th><th>Description</th><th>SNP</th><th>Chr</th><th>Position</th><th>Allele</th><th>Minor allele</th><th>MAF</th><th>d</th></t<></thc> | Gene | Traits | Description | SNP | Chr | Position | Allele | Minor allele | MAF | d |
|--|--------------------|--------|--|-------------|-----|-----------|--------|--------------|-------|----------|
| Distribution Distribution contribution contribution< | DLG1-AS1;LINC02012 | FPI | DLG1 antisense RNA1 | rs78022276 | с | 197482798 | 1/C | Т | 0.029 | 2.88E-06 |
| GMS71 FI Somtimiented with selection | DLG1-AS1;LINC02012 | FPI | DLG1 antisense RNA1 | rs78750477 | с | 197483030 | C/G | U | 0.029 | 2.88E-06 |
| CIGE11P FII Condition | SORCS1 | FPI | Sortilin related VPS10 domain containing receptor | rs58879794 | 10 | 106889263 | C/A | U | 0.150 | 3.94E-06 |
| CIGET1P FH CIAGE family member 11, peudopene 1512330 15 7512330 AG AG 37566 CIAGET1P FH Zury 19 FH 2073 12 7512330 AG 7512460 75 76 751566 ZIVET19 ZhP Zury 19 Zury 19 7512400 TC T 0.454 25166 ZIVET19 ZhP Zury 19 2014 C T 0.446 2.0550 ZIVET10 ZhP 2014 C 10 10 10 0.446 2.0550 MARCH2 ZhP 2014 C 10 0.447 2.0550 0.0567 MARCH2 ZhP 2014 C 0 0.440 0.466 2.0550 MARCH2 ZhP 2014 C 0 0.441 0.466 0.466 0.466 0.466 0.466 0.466 0.466 0.466 0.466 0.466 0.466 0.466 0.466 0.466 0.466 | CTAGE11P | FPI | | rs9600432 | 13 | 75107716 | A/C | A | 0.453 | 1.42E-06 |
| CIGE11P FII cs63-38.2 13 751-00.0 17 0.446 251-00 ZM718 Zm6 finge rotin18 ss61.285.4 4 182.33 1/C 1 0.446 5.86.00 ZM718 Zm6 finge rotin18 sr61.285.4 4 182.33 1/C 1 0.446 5.86.00 ZM718 Zm6 finge rotin18 sr29.137 19 842.148 C 1 0.46 2.96.00 MARCH2 ZhP March2 ZhP 1 2.017 19 842.148 C 1 0.46 2.96.00 MARCH2 ZhP March2 2.017 19 842.148 C 1 0.46 2.96.00 MARCH2 ZhP St6.1752 19 842.148 C 1 0.46 2.96.00 MARCH2 ZhP St6.1752 19 842.148 C 1 0.46 2.96.01 MARCH2 ZhP St6.1752 19 842.148 C 1 < | CTAGE11P | FPI | CTAGE family member 11, preudogene | rs9565135 | 13 | 75122830 | A/G | A | 0.454 | 3.75E-06 |
| ZMT16 ZM Zm (mger (more)) Zm (mger | CTAGE11P | FPI | | rs9543852 | 13 | 75124005 | 1/G | Т | 0.454 | 2.51E-06 |
| ZH716 Zub methonence Sebacat 4 12200 V.C 1 0.446 2.416.00 MACHEZ Zh Zh Sebacat Sebaca Sebaca <td>ZNF718</td> <td>2hPI</td> <td>Zino Encore states and Cont</td> <td>rs56128594</td> <td>4</td> <td>188333</td> <td>1/C</td> <td>Т</td> <td>0.446</td> <td>5.88E-08</td> | ZNF718 | 2hPI | Zino Encore states and Cont | rs56128594 | 4 | 188333 | 1/C | Т | 0.446 | 5.88E-08 |
| MARCH72 2h1 csi23739 csi23739 csi23739 csi23739 csi23739 csi23739 csi23733 csi23733 csi23733 csi23733 csi23733 csi23733 csi23733 csi23733 csi23733 csi237333 csi237333 csi237333 csi237333 csi237333 csi237333 csi237333 csi237333 csi237333 csi233333 csi2333333 csi2333333 csi2333333 csi2333333 csi2333333 csi23333333 csi2333333 csi23333333333 csi233333333 csi23 | ZNF718 | 2hPI | | rs4690234 | 4 | 192200 | 1/C | Т | 0.446 | 2.41E-08 |
| MARCHEZ 20H 64014 CT C 0.465 2.02668 MARCHEZ 2hH memberasociated ing-CH-type 1523919 19 843167 C C 0.465 2.026.08 MARCHEZ 2hH memberasociated ing-CH-type 1525939 19 843516 C C 0.445 8.96-CD MARCHEZ 2hH 7hH 2hH 7hH C 0.445 8.96-CD MARCHEZ 2hH 7hH 843568 176 C 0.445 8.96-CD MARCHEZ 2hH 7hH 843605 19 843605 7 7 0.445 8.96-CD MARCHEZ 2hH 843605 19 843605 7 7 0.445 8.96-CD MARCHEZ 2hH 843605 19 843605 7 7 0.445 126-CD MARCHEZ 2hH 843605 19 843605 7 7 0.445 126-CD MARCHEZ 2hH< | MARCHF2 | 2hPI | | rs12979798 | 19 | 8419748 | G/A | 9 | 0.395 | 4.05E-07 |
| MARCHEZ ZhPl Membane associated ring-CH-type 5211527 19 8421448 C/T C 0.405 2.026.08 MARCHEZ ZhPl fingerZ resociated ring-CH-type resociated ring-CH-type resociated ring-CH-type resociated ring-CH-type 2.026.08 2.026.08 2.026.08 MARCHEZ ZhPl resociated ring-CH-type resociated ring-CH-type resociated ring-CH-type 8.935.05 1/0 C/T C 0.445 8.996.07 MARCHEZ ZhPl resociated ring-CH-type resociated ring-CH-type resociated ring-CH-type resociated ring-CH-type 8.935.05 1/0 C/T C 0.445 8.996.07 MARCHEZ ZhPl resociated ring-CH-type resociated ring-CH-type resociated ring-CH-type resociated ring-CH-type 8.936.07 1/0 C/T C 0.445 8.946.07 MARCHEZ ZhPl resociated ring-CH-type resociated ring-CH-type resociated ring-CH-type 8.946.07 1/0 0/10 1/0 0/10 1/0 1/0 1/0 1/0 | MARCHF2 | 2hPI | | rs12978137 | 19 | 8420144 | C/T | U | 0.405 | 2.02E-08 |
| MARCH-Z Inger 2 Inger 2 Inger 2 Inger 2 Inger 3 Inger 3 <t< td=""><td>MARCHF2</td><td>2hPI</td><td>- Membrane associated ring-CH-type</td><td>rs62117527</td><td>19</td><td>8421448</td><td>C/T</td><td>U</td><td>0.405</td><td>2.02E-08</td></t<> | MARCHF2 | 2hPI | - Membrane associated ring-CH-type | rs62117527 | 19 | 8421448 | C/T | U | 0.405 | 2.02E-08 |
| MARCHF2 2h1 is1297669 is is3552870 is | MARCHF2 | 2hPI | finger 2 | rs11259979 | 19 | 8435167 | C/T | C | 0.444 | 8.99E-07 |
| MARHF2 ZPH is35562870 19 843620 C/T C 0.445 8.46-07 HMRNPM ZPH ZPH is17160491 19 8448056 T/G T 0.445 8.46-07 HMRNPM ZPH ZPH is17160491 19 8448056 T/G T 0.469 9.476-07 HNRNPM ZPH Z | MARCHF2 | 2hPI | | rs12975669 | 19 | 8435935 | D/T | Т | 0.445 | 1.20E-06 |
| HMRMPM ZhPl rs1160491 19 844805 T/G T 0.469 9.47E-07 HNRMPM ZhPl rs2081197 19 844805 KG A 0.439 7.83E-07 HNRMPM ZhPl rs2081197 19 844901 A/C A 0.439 7.83E-07 HNRMPM ZhPl rs11666117 19 8449010 A/C A 0.431 6.15E-07 HNRMPM ZhPl rs1155983 19 8450732 T/A T 0.441 6.15E-07 HNRNPM ZhPl rs1166495 19 8450732 T/A T 0.447 2.15E-06 HNRNPM ZhPl rs1166495 19 8450732 T/A T 0.447 2.15E-06 HNRNPM ZhPl rs1166495 19 8450732 T/A T 0.447 2.15E-06 HNRNPM ZhPl rs116495 19 8450732 T/A T 2.15E-07 HNRNPM | MARCHF2 | 2hPI | | rs35562870 | 19 | 8436208 | C/T | C | 0.445 | 8.84E-07 |
| Innorm ZPI rs2081197 19 848452 AC A 0.439 1.38507 Innorm ZPI Innorm ZPI Innorm A C A 0.439 1.38507 Innorm ZPI Innorm ZPI Innorm A A 0.447 C A 0.447 C A C A C A C A C A C A C C C A C < | HNRNPM | 2hPI | | rs17160491 | 19 | 8448056 | J/L | Т | 0.469 | 9.47E-07 |
| INRNPM ZhPl rs11666117 19 8449010 AC A 0.441 6.15E07 HNRNPM ZhPl rs11259983 19 8450491 AC A 0.447 6.15E07 HNRNPM ZhPl rs11259983 19 8450431 AC A 0.447 6.15E07 HNRNPM ZhPl rs1126983 19 845032 17A 17 0.460 7 0.460 7.15E06 HNRNPM ZhPl rs1160495 19 8451394 AT 0.47 0.470 0.470 0.470 0.470 HNRNPM ZhPl rs1160495 19 8451394 AT A 0.447 4.20E07 HNRNPM ZhPl rs1160495 19 8451393 AT A 0.447 4.20E07 HNRNPM ZhPl rs1160495 19 8451393 AT A 0.447 4.20E07 HNRNPM ZhPl rs1193 AT A 0.441 0.414< | HNRNPM | 2hPI | | rs2081197 | 19 | 8448452 | A/C | A | 0.439 | 7.83E-07 |
| HIRUPM ZhP1 (51259983) (5) (4504) (4) (4,206-0) (4,10) (4,206-0) HIRUPM ZhP1 (5) | HNRNPM | 2hPI | | rs11666117 | 19 | 8449010 | A/C | A | 0.441 | 6.15E-07 |
| HRNPM ZhP1 rs868781681 19 8450732 T/A T 0.460 2.17E-06 HNRNPM ZhP1 rs200358539 19 8450735 T/A T 0.459 1.97E-06 HNRNPM ZhP1 Herogeneous nuclear rs200358539 19 8451735 T/A T 0.459 1.97E-06 HNRNPM ZhP1 Hibouclaoprotein M rs1760495 19 8451793 AT A 0.447 4.20E-07 HNRNPM ZhP1 Recogeneous nuclear rs1750985 19 8451339 A/T A 0.447 4.20E-07 HNRNPM ZhP1 Recogeneous nuclear rs17503 19 8454339 A/G A 0.447 4.20E-07 HNRNPM ZhP1 Recogeneous nuclear rs34344585 19 8458333 A/G A 0.441 6.40E-07 HNRNPM ZhP1 Recogeneous nuclear rs3444556 19 8458333 A/G A 0.441 6.40E-07 | HNRNPM | 2hPI | | rs11259983 | 19 | 8450491 | A/C | А | 0.447 | 4.20E-07 |
| HNRNPM ZhPI Testonas Testonas <thtestonas< th=""> <thtestonas< th=""> <thtest< td=""><td>HNRNPM</td><td>2hPI</td><td></td><td>rs868781681</td><td>19</td><td>8450732</td><td>T/A</td><td>Т</td><td>0.460</td><td>2.17E-06</td></thtest<></thtestonas<></thtestonas<> | HNRNPM | 2hPI | | rs868781681 | 19 | 8450732 | T/A | Т | 0.460 | 2.17E-06 |
| HIRNPM ZhPI Heterogeneous nuclear rs17160495 19 8451394 AT A 0.447 4.20E-07 HNRNPM ZhPI ibonuclaoprotein M rs1125995 19 8451793 AT A 0.447 4.20E-07 HNRNPM ZhPI ribonuclaoprotein M rs1125995 19 8451793 AT A 0.447 4.20E-07 HNRNPM ZhPI rs3423793 19 845339 AG A 0.447 3.61E-07 HNRNPM ZhPI rs3424685 19 8458122 T/C T 0.441 6.40E-07 HNRNPM ZhPI rs3764570 19 8465033 A/G A 0.446 3.38E-07 HNRNPM ZhPI rs3794997 19 8465033 A/G A 0.446 3.38E-07 HNRNPM ZhPI rs3794997 19 8465033 A/G A 0.446 3.38E-07 HNRNPM ZhPI rs3445564 19 8465033 | HNRNPM | 2hPI | | rs200358539 | 19 | 8450735 | T/A | Т | 0.459 | 1.97E-06 |
| HNRNPM ZhP1 rs1125995 19 8451793 AT A 0.447 4.20E-07 HNRNPM ZhP1 ZhP1 rs34337793 19 8454339 A/G A 0.447 3.61E-07 HNRNPM ZhP1 rs34337793 19 8456339 A/G A 0.447 3.61E-07 HNRNPM ZhP1 rs344665 19 8458122 T/C T 0.446 3.36E-07 HNRNPM ZhP1 T 19 8463393 A/G A 0.446 3.38E-07 HNRNPM ZhP1 19 8465003 A/T A 0.446 3.38E-07 HNRNPM ZhP1 19 8468214 A/T A 0.446 3.38E-07 | HNRNPM | 2hPI | Heterogeneous nuclear rihonuclaonrotein M | rs17160495 | 19 | 8451394 | A/T | A | 0.447 | 4.20E-07 |
| HNRNPM ZhP1 rs34337793 19 8454339 A/G A 0.447 3.61E-07 HNRNPM ZhP1 zhP1 rs34244685 19 8458122 T/C T 0.441 6.40E-07 HNRNPM ZhP1 rs3764570 19 845333 A/G A 0.446 3.38E-07 HNRNPM ZhP1 rs3764570 19 8463393 A/G A 0.446 3.38E-07 HNRNPM ZhP1 rs3744564 19 8468214 A/T A 0.446 3.38E-07 HNRNPM ZhP1 rs3445564 19 8468214 A/T A 0.439 6.01E-07 | HNRNPM | 2hPI | | rs11259985 | 19 | 8451793 | A/T | A | 0.447 | 4.20E-07 |
| HNRNPM ZhPI rs3424685 19 8458122 T/C T 0.41 6.40E-07 HNRNPM ZhPI ZhPI rs3764570 19 8463393 A/G A 0.446 3.38E-07 HNRNPM ZhPI rs3764570 19 8463033 A/G A 0.446 3.38E-07 HNRNPM ZhPI rs3744564 19 8468214 A/T A 0.439 6.01E-07 | HNRNPM | 2hPI | | rs34337793 | 19 | 8454339 | A/G | A | 0.447 | 3.61E-07 |
| HNRNPM ZhPI rs3764570 19 8463393 A/G A 0.446 3.38E-07 HNRNPM ZhPI vs3794997 19 8465003 A/T A 0.446 3.38E-07 HNRNPM ZhPI vs37445564 19 8468214 A/T A 0.439 6.01E-07 | HNRNPM | 2hPI | | rs34244685 | 19 | 8458122 | 1/C | Т | 0.441 | 6.40E-07 |
| HNRNPM ZhPI rs3794997 19 8465003 A/T A 0.446 3.38E-07 HNRNPM ZhPI P 8468214 A/T A 0.439 6.01E-07 | HNRNPM | 2hPI | | rs3764570 | 19 | 8463393 | A/G | A | 0.446 | 3.38E-07 |
| HNRNPM 2hPI rs3445564 19 8468214 A/T A 0.439 6.01E-07 | HNRNPM | 2hPI | | rs3794997 | 19 | 8465003 | A/T | А | 0.446 | 3.38E-07 |
| | HNRNPM | 2hPI | | rs34445564 | 19 | 8468214 | A/T | A | 0.439 | 6.01E-07 |

GWAS of proinsulin/insulin in Chinese Han people

| Gene | Traits | Description | SNP | Chr | Position | Allele | Minor allele | MAF | d |
|--|--------------|--|-------------|-----|-----------|--------|--------------|-------|----------|
| HNRNPM | 2hPI | | rs17159302 | 19 | 8469632 | A/C | А | 0.439 | 6.01E-07 |
| HNRNPM | 2hPI | | rs17159303 | 19 | 8469677 | G/A | 5 | 0.446 | 3.38E-07 |
| HNRNPM | 2hPI | Heterogeneous nuclear | rs74180130 | 19 | 8479935 | C/T | J | 0.452 | 1.19E-06 |
| HNRNPM | 2hPI | ribonuclaoprotein M | rs17160520 | 19 | 8483705 | G/A | 5 | 0.453 | 1.01E-06 |
| HNRNPM | 2hPI | | rs2277987 | 19 | 8487389 | A/G | A | 0.440 | 5.76E-08 |
| HNRNPM | 2hPI | | rs1599870 | 19 | 8488516 | G/A | 5 | 0.440 | 6.62E-08 |
| KRT71 | ш | | rs12308719 | 12 | 52548451 | G/T | 9 | 0.482 | 2.31E-06 |
| KRT71 | ш | | rs10876309 | 12 | 52548517 | C/T | J | 0.482 | 2.31E-06 |
| KRT71 | Ē | 14 N | rs3803084 | 12 | 52548843 | A/G | A | 0.495 | 1.02E-06 |
| KRT71 | Ē | | rs3803085 | 12 | 52548910 | C/T | J | 0.483 | 1.08E-06 |
| KRT71 | Ē | | rs4761930 | 12 | 52549360 | G/A | 5 | 0.487 | 1.52E-06 |
| KRT71 | Ē | | rs4761933 | 12 | 52555091 | C/T | J | 0.491 | 2.12E-06 |
| UBE2U | 2hl | Ubiquitin conjugating enzyme E2 U | rs11585260 | - | 64315831 | G/C | 5 | 0.024 | 4.94E-06 |
| UBE2U | 2hl | | rs11577590 | - | 64315842 | C/G | J | 0.024 | 4.94E-06 |
| ABO | 2hl | | rs9411372 | 6 | 133258677 | A/G | A | 0.138 | 9.59E-07 |
| ABO | 2hl | | rs977371848 | 6 | 133266456 | 1/C | T | 0.163 | 1.56E-07 |
| ABO | 2hl | | rs879055593 | 6 | 133271182 | 1/C | T | 0.163 | 1.56E-07 |
| ABO | 2hl | | rs992108547 | 6 | 133273983 | A/G | A | 0.163 | 1.56E-07 |
| ABO | 2hl | Alpha | rs947073006 | 6 | 133274414 | A/G | A | 0.163 | 1.56E-07 |
| ABO | 2hl | 1-5-IN-acetylgalactosammyltiansierase and alpha 1-3-galactosaminyltransferase | rs600038 | 6 | 133276354 | C/T | J | 0.159 | 7.95E-07 |
| ABO | 2hl | | rs651007 | 6 | 133278431 | 1/C | T | 0.159 | 3.84E-07 |
| ABO | 2hl | | rs579459 | 6 | 133278724 | C/T | C | 0.159 | 3.84E-07 |
| ABO | 2hl | | rs495828 | 6 | 133279294 | D/T | T | 0.159 | 3.84E-07 |
| ABO | 2hl | | rs635634 | 6 | 133279427 | 1/C | T | 0.159 | 3.84E-07 |
| LINC01520;GRID1-AS1 | 2hl | | rs375709957 | 10 | 85558056 | T/A | T | 0.176 | 1.87E-06 |
| LINC01520;GRID1-AS1 | 2hl | UNIU I AUTISENSE KINA I | rs77136415 | 10 | 85558059 | T/C | Т | 0.176 | 1.87E-06 |
| SNP — single nucleotide polyphormisms; | Chr — chromo | some; MAF — minor allele frequency | | | | | | | |

Table 2. Significant loci associated with fasting proinsulin (FPI), 2h proinsulin (2hPI), fasting insulin (FI), and 2h insulin (2hI) in study populations



Figure. 1 *Manhattan plot for loci associated with fasting proinsulin (FPI)* (**A**), 2-hour postprandial proinsulin (2hPI) (**B**), fasting insulin (FI) (**C**), and 2-hour postprandial insulin (2hI) (**D**)

a small percentage of the total variation in FPI and FI. In the present study, we found 6 SNPs in *DLG1-AS1*, *SORCS1*, and *CTAGE11P* for FPI, 27 SNPs in *ZNF718*, *MARCHF2*, and *HNRNPM* for 2hPI, 6 SNPs in *KRT71* for FI, and 14 SNPs in *UBE2U*, *ABO*, and *GRID1-AS1* for 2hI. Among these, the genetic variants of *CTAGE11P*, *MARCHF2*, *KRT71*, and *ABO* have the strongest association with FPI, 2hPI, FI, and 2hI.

The E3 ubiquitin ligase membrane-associated ring-CH-type finger 2 (*MARCHF2*) is a member of the membrane-associated RING-CH E3 ubiquitin ligase family (*MARCH*) and localizes to the endoplasmic reticulum and Golgi [20]. The known substrate of *MARCHF2* includes cystic fibrosis transmembrane conductance regulator (*CFTR*) [21]. Some studies have indicated that patients with *CFTR* gene variants show an insufficiency of insulin secretion, leading to the development of DM

[22, 23]. Moreover, Khan et al. found that inhibition of *CFTR* decreased the concentrations of plasma insulin and pancreatic insulin in *CFTR*-inhibited animals [24]. Another study demonstrated that the mutation of *CFTR* is associated with insulin resistance and decreased β -cell mass in mice [25]. This evidence led us to believe that *MARCHF2* is involved in the development of pancreas and DM by interacting with *CFTR*.

Keratin 71 (*KRT71*) is a member of the keratin family and is located on chromosome 12q13.13. Keratin constitutes the intermediate filament proteins of epithelial cells. It is documented that the loss of keratin 8 decreased fasting blood glucose levels, and increased glucose uptake and glycogen synthesis [26, 27]. The abnormal expression of keratin 1 and 10 reduced insulin secretion, thus leading to the development of DM [28]. The ABO gene encodes glycosyltransferases that catalyse the transfer of nucleotide donor sugars to the H antigen to form the A and B antigens. Variation in the ABO gene is the basis of the ABO blood group. Meo et al. found that blood group "B" is associated with a higher risk of T2DM, while blood group "O" has a weak correlation with T2DM [29]. Also, a GWAS reported that ABO variants are associated with increased levels of plasma lipid and soluble intercellular adhesion molecule 1 and tumour necrosis factor 2 (TNF-2). These molecules could affect insulin and its receptors and contribute to the development of DM [30].

CTAGE family member 11 pseudogene (*CTAGE11P*) belongs to the cutaneous T-cell lymphoma-associated antigen (CTAGE) family and is located on 13q22.2. It is reported that the mutation of family members reduces cholesterol and triglyceride levels in mice [31]. Another family member can regulate the plasma low-density lipoprotein-cholesterol concentration and is associated with coronary artery disease [32]. Our study found for the first time that *CTAGE11P* genetic variants are associated with FPI in the Chinese people.

Conclusions

We found that the genetic variants of *CTAGE11P*, *MARCHF2*, *KRT71*, and *ABO* are significantly correlated with FPI, 2hPI, FI, and 2hI in Chinese Han people, respectively. These genetic variants may serve as new biomarkers for the prevention of prediabetes.

Conflict of interest

All authors declare that they have no competing interests.

Funding

This study received the support of the major research and development program of Hainan Province (no. ZDYF2021SHFZ078), and received the support of project supported by Hainan Province Clinical Medical Center.

Acknowledgments

The authors thank all participants and volunteers in this study. We also thank the Hainan Affiliated Hospital of Hainan Medical University for their help with sample collections.

Data availability statement

The data that support the findings of this study are available from the supporting information files of this manuscript.

Ethical approval

This study was conducted with ethical approval from the Hainan Affiliated Hospital of Hainan Medical University Ethics Committees, and it was performed in line with the Declaration of Helsinki. We also obtained consent forms signed by each participant.

Consent to participate

Not applicable.

Code availability

Not applicable.

Authors' contributions

Le.L. and H.Q. designed this study protocol and drafted the manuscript; T.F. and Lu.L. performed the DNA extraction and genotyping; Q.O. performed the data analysis; H.Z. performed the sample collection and information recording; K.C. and Z.Z. revised the manuscript; H.Q. conceived and supervised the study. All authors read and approved the final manuscript.

References

- Shi Y, Hu FB. The global implications of diabetes and cancer. Lancet. 2014; 383(9933): 1947–1948, doi: 10.1016/S0140-6736(14)60886-2, indexed in Pubmed: 24910221.
- Tao Z, Shi A, Zhao J. Epidemiological Perspectives of Diabetes. Cell Biochem Biophys. 2015; 73(1): 181–185, doi: 10.1007/s12013-015-0598-4, indexed in Pubmed: 25711186.
- Tabák AG, Herder C, Rathmann W, et al. Prediabetes: a high-risk state for diabetes development. Lancet. 2012; 379(9833): 2279–2290, doi: 10.1016/S0140-6736(12)60283-9, indexed in Pubmed: 22683128.
- Wang L, Gao P, Zhang M, et al. Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013. JAMA. 2017; 317(24): 2515–2523, doi: 10.1001/jama.2017.7596, indexed in Pubmed: 28655017.
- Selvin E, Lazo M, Chen Y, et al. Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage. Circulation. 2014; 130(16): 1374–1382, doi: 10.1161/CIRCULATIONAHA.114.010815, indexed in Pubmed: 25149362.
- Brannick B, Wynn A, Dagogo-Jack S. Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications. Exp Biol Med (Maywood). 2016; 241(12): 1323–1331, doi: 10.1177/1535370216654227, indexed in Pubmed: 27302176.
- Priya G. Management of prediabetes. J Pak Med Assoc. 2018; 68(4): 669–671, indexed in Pubmed: 29808066.
- Dall TM, Yang W, Gillespie K, et al. The Economic Burden of Elevated Blood Glucose Levels in 2017: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes. Diabetes Care. 2019; 42(9): 1661–1668, doi: 10.2337/dc18-1226, indexed in Pubmed: 30940641.
- Pfützner A, Kunt T, Hohberg C, et al. Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care. 2004; 27(3): 682–687, doi: 10.2337/diacare.27.3.682, indexed in Pubmed: 14988285.
- Vangipurapu J, Stančáková A, Kuulasmaa T, et al. Both fasting and glucose-stimulated proinsulin levels predict hyperglycemia and incident type 2 diabetes: a population-based study of 9,396 Finnish men. PLoS One. 2015; 10(4): e0124028, doi: 10.1371/journal.pone.0124028, indexed in Pubmed: 25853252.
- Pfützner A, Forst T. Elevated intact proinsulin levels are indicative of Beta-cell dysfunction, insulin resistance, and cardiovascular risk: impact of the antidiabetic agent pioglitazone. J Diabetes Sci Technol. 2011; 5(3): 784–793, doi: 10.1177/193229681100500333, indexed in Pubmed: 21722594.
- 12. Falkner B. Insulin resistance in African Americans. Kidney Int. 2003; 63: S27–S30, doi: 10.1046/j.1523-1755.63.s83.7.x.
- Quan H, Fang T, Lin L, et al. The correlation between proinsulin, true insulin, proinsulin: True insulin ratio, 25(OH) D3, waist circumference and risk of prediabetes in Hainan Han adults. PLoS One. 2020; 15(9): e0238095, doi: 10.1371/journal.pone.0238095, indexed in Pubmed: 32881889.
- Li Y, Teng Di, Shi X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ. 2020; 369: m997, doi: 10.1136/bmj.m997, indexed in Pubmed: 32345662.
- Ding Y, Yang D, Zhou L, et al. Variants in multiple genes polymorphism association analysis of COPD in the Chinese Li population. Int J Chron Obstruct Pulmon Dis. 2015; 10: 1455–1463, doi: 10.2147/COPD.S86721, indexed in Pubmed: 26251585.
- 16. Strawbridge RJ, Dupuis J, Prokopenko I, et al. DIAGRAM Consortium, GIANT Consortium, MuTHER Consortium, CARDIoGRAM Consortium, C4D Consortium. Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. Diabetes. 2011; 60(10): 2624–2634, doi: 10.2337/db11-0415, indexed in Pubmed: 21873549.
- Huyghe JR, Jackson AU, Fogarty MP, et al. Exome array analysis identifies new loci and low-frequency variants influencing insulin processing and secretion. Nat Genet. 2013; 45(2): 197–201, doi: 10.1038/ng.2507, indexed in Pubmed: 23263489.

- Willems SM, Cornes BK, Brody JA, et al. Association of the IGF1 gene with fasting insulin levels. Eur J Hum Genet. 2016; 24(9): 1337–1343, doi: 10.1038/ejhg.2016.4, indexed in Pubmed: 26860063.
- Manning AK, Hivert MF, Scott RA, et al. DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium, Multiple Tissue Human Expression Resource (MUTHER) Consortium. A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet. 2012; 44(6): 659–669, doi: 10.1038/ng.2274, indexed in Pubmed: 22581228.
- Bartee E, Mansouri M, Hovey Nerenberg BT, et al. Downregulation of major histocompatibility complex class I by human ubiquitin ligases related to viral immune evasion proteins. J Virol. 2004; 78(3): 1109–1120, doi: 10.1128/jvi.78.3.1109-1120.2004, indexed in Pubmed: 14722266.
- Xia D, Qu L, Li Ge, et al. MARCH2 regulates autophagy by promoting CFTR ubiquitination and degradation and PIK3CA-AKT-MTOR signaling. Autophagy. 2016; 12(9): 1614–1630, doi: 10.1080/15548627.2016.1192 752, indexed in Pubmed: 27308891.
- 22. Konrad K, Scheuing N, Badenhoop K, et al. Cystic fibrosis-related diabetes compared with type 1 and type 2 diabetes in adults. Diabetes Metab Res Rev. 2013; 29(7): 568–575, doi: 10.1002/dmrr.2429, indexed in Pubmed: 23704008.
- Noronha RM, Calliari LE, Damaceno N, et al. Update on diagnosis and monitoring of cystic fibrosis-related diabetes mellitus (CFRD). Arq Bras Endocrinol Metabol. 2011; 55(8): 613–621, doi: 10.1590/s0004-27302011000800016, indexed in Pubmed: 22218444.
- Khan D, Kelsey R, Maheshwari RR, et al. Short-term CFTR inhibition reduces islet area in C57BL/6 mice. Sci Rep. 2019; 9(1): 11244, doi: 10.1038/s41598-019-47745-w, indexed in Pubmed: 31375720.
- Fontés G, Ghislain J, Benterki I, et al. The F508 Mutation in the Cystic Fibrosis Transmembrane Conductance Regulator Is Associated With

Progressive Insulin Resistance and Decreased Functional β -Cell Mass in Mice. Diabetes. 2015; 64(12): 4112–4122, doi: 10.2337/db14-0810, indexed in Pubmed: 26283735.

- Mathew J, Loranger A, Gilbert S, et al. Keratin 8/18 regulation of glucose metabolism in normal versus cancerous hepatic cells through differential modulation of hexokinase status and insulin signaling. Exp Cell Res. 2013; 319(4): 474–486, doi: 10.1016/j.yexcr.2012.11.011, indexed in Pubmed: 23164509.
- Alam CM, Silvander JSG, Daniel EN, et al. Keratin 8 modulates β-cell stress responses and normoglycaemia. J Cell Sci. 2013; 126(Pt 24): 5635–5644, doi: 10.1242/jcs.132795, indexed in Pubmed: 24144696.
- Blessing M, Rüther U, Franke WW. Ectopic synthesis of epidermal cytokeratins in pancreatic islet cells of transgenic mice interferes with cytoskeletal order and insulin production. J Cell Biol. 1993; 120(3): 743–755, doi: 10.1083/jcb.120.3.743, indexed in Pubmed: 7678835.
- Meo SA, Rouq FA, Suraya F, et al. Association of ABO and Rh blood groups with type 2 diabetes mellitus. Eur Rev Med Pharmacol Sci. 2016; 20(2): 237–242, indexed in Pubmed: 26875891.
- Langari SH, Bahar A, Asadian L, et al. Coronary Heart Disease and ABO Blood Group in Diabetic Women: A Case-Control Study. Sci Rep. 2019; 9(1): 7441, doi: 10.1038/s41598-019-43890-4, indexed in Pubmed: 31092877.
- Pitman JL, Bonnet DJ, Curtiss LK, et al. Reduced cholesterol and triglycerides in mice with a mutation in Mia2, a liver protein that localizes to ER exit sites. J Lipid Res. 2011; 52(10): 1775–1786, doi: 10.1194/jlr.M017277, indexed in Pubmed: 21807889.
- Zaimkohan H, Keramatipour M, Mirhafez SR, et al. The Relationship Between Coronary Artery Disease and Genetic Polymorphisms of Melanoma Inhibitory Activity 3. Iran Red Crescent Med J. 2016; 18(9): e31146, doi: 10.5812/ircmj.31146, indexed in Pubmed: 28180021.